Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis

Technology appraisal guidance
Reference number: TA276
Published: 27 March 2013

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Novartis comments

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Novartis comments

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Novartis comments
25 January 2013
(251.06 Kb 13 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 23 January 2013